Mumbai, Sept. 28 -- Zydus Lifesciences announced that the USFDA conducted onsite inspection of pharmacovigilance and post marketing surveillance system at the company's office based in New Jersey, USA. The inspection was conducted from 22 September to 25 September 2026. The inspection closed with NIL observations.

Published by HT Digital Content Services with permission from Capital Market....